~~<i id='E7DFD58D34'><strike id='E7DFD58D34'><tt id='E7DFD58D34'><pre id='E7DFD58D34'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：hotspot 2025-10-01 21:40:22 - browse：9

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Do more moles mean more problems? Not so, says new study

Wikipedia

hotspot

focus

Wikipedia

leisure time

entertainment

DavidSabatiniposedathishomeinCambridgein2022.CraigF.Walker/BostonGlobeFormerMITandWhiteheadInstitute

WSS

Intercept Pharmaceuticals sells itself for less than $1 billion

Covid vaccines: Private market messier than government rollout

Akili, maker of video game for ADHD, to be acquired for 34 million

First Opinion Podcast: What happens when kids become caregivers?

Biohaven protein

STAT Virtual Event: How to Increase Diversity in Clinical Trials

hotspot

Wikipedia

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Anesthesiologist group: stop taking Ozempic before surgery

Scientists successfully use ultrasound imaging to map brain activity

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

iTeos Therapeutics debuts first data on TIGIT

Affirmative action in medical school literally saved lives

Mindstrong's demise and the future of mental health care

hotspot

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Listen: Who gets the credit for GLP

Biohaven protein

Sudafed saga points to U.S. issues with evaluating older drugs

How the Dana

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

focus

Wikipedia

leisure time

entertainment